TIKOMED AB
- Home
- Companies
- TIKOMED AB
- Products
- IBSOLVMIR - Infusion Drugs
IBSOLVMIR - Infusion Drugs
FromTIKOMED AB
Cell therapies are associated with graft loss. It involves activation of the complement and coagulation cascades when cells come into contact with blood, ultimately resulting in cell death. IBSOLVMIR is an infusion product that inhibits IBMIR and alleviates its detrimental effects when administered during transplantation. In addition, IBSOLVMIR help cells pass through the lung and reach their intended site and once there, it promotes the formation of new vessels and engraftment.
Most popular related searches
regenerative cell therapy
cell therapy
infusion product
diabetes patient
infusion drug
T-cell
diabetes
chronic diabetes
in vitro cell
pancreas
- Developed to improve islet cell transplantation for treatment of patients with severe diabetes and chronic pancreatitis
- Suitable for use with several cell types
- Applicable to a range of regenerative cell therapies
- Improves viability of engrafted cells resulting in higher efficacy and improved patient outcomes
Independent studies have demonstrated:
- Improved in vitro viability of islet cells (Naziruddin 2014).
- Improved survival of EPO producing CHO cells (Menviele et al 2013).
- Improved survival and engraftment of HSC in mice (Hayakawa et al 2009).
- Inhibition of the ability of human islets to trigger IBMIR (Johansson et al 2006).
- Reduces entrapment of T-cells in the lung
- Improved survival of engrafted myoblasts in mice (Laumonier et al 2013).
- Increased the survival of grafted adult porcine islets after intraportal transplantation into diabetic athymic mice (Goto et al 2004).